These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1126 related articles for article (PubMed ID: 26852372)

  • 1. The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease.
    Benskey MJ; Perez RG; Manfredsson FP
    J Neurochem; 2016 May; 137(3):331-59. PubMed ID: 26852372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease.
    Faustini G; Longhena F; Varanita T; Bubacco L; Pizzi M; Missale C; Benfenati F; Björklund A; Spano P; Bellucci A
    Acta Neuropathol; 2018 Oct; 136(4):621-639. PubMed ID: 30046897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of functional alpha-synuclein: a toxic event in Parkinson's disease?
    Kanaan NM; Manfredsson FP
    J Parkinsons Dis; 2012; 2(4):249-67. PubMed ID: 23938255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.
    Sahay S; Ghosh D; Singh PK; Maji SK
    Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α-Synuclein aggregation and transmission in Parkinson's disease: a link to mitochondria and lysosome.
    Wang R; Sun H; Ren H; Wang G
    Sci China Life Sci; 2020 Dec; 63(12):1850-1859. PubMed ID: 32681494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of alpha-synuclein oligomerization and aggregation in cellular and animal models of Parkinson's disease.
    Wan OW; Chung KK
    PLoS One; 2012; 7(6):e38545. PubMed ID: 22701661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research Progress of α-Synuclein Aggregation Inhibitors for Potential Parkinson's Disease Treatment.
    Kalsoom I; Wang Y; Li B; Wen H
    Mini Rev Med Chem; 2023; 23(20):1959-1974. PubMed ID: 37198991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
    Mehra S; Sahay S; Maji SK
    Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease.
    Sharma N; Rao SP; Kalivendi SV
    Free Radic Biol Med; 2019 May; 135():28-37. PubMed ID: 30796974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Overview on the Role of α -Synuclein in Experimental Models of Parkinson's Disease from Pathogenesis to Therapeutics.
    Javed H; Kamal MA; Ojha S
    CNS Neurol Disord Drug Targets; 2016; 15(10):1240-1252. PubMed ID: 27658511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
    Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological inhibition and knockdown of O-GlcNAcase reduces cellular internalization of α-synuclein preformed fibrils.
    Tavassoly O; Yue J; Vocadlo DJ
    FEBS J; 2021 Jan; 288(2):452-470. PubMed ID: 32365408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of age-associated alpha-synuclein aggregation in a conditional transgenic mouse model of Parkinson's disease: Implications for Lewy body formation.
    Li J; Ng KW; Sung CC; Chung KKK
    J Neurochem; 2024 Jul; 168(7):1215-1236. PubMed ID: 38693066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-aggregation of pro-inflammatory S100A9 with α-synuclein in Parkinson's disease: ex vivo and in vitro studies.
    Horvath I; Iashchishyn IA; Moskalenko RA; Wang C; Wärmländer SKTS; Wallin C; Gräslund A; Kovacs GG; Morozova-Roche LA
    J Neuroinflammation; 2018 Jun; 15(1):172. PubMed ID: 29866153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
    Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
    Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
    Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D
    Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α-synuclein aggregation and its modulation.
    Ghosh D; Mehra S; Sahay S; Singh PK; Maji SK
    Int J Biol Macromol; 2017 Jul; 100():37-54. PubMed ID: 27737778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease.
    Xu S; Chan P
    Biomolecules; 2015 Jun; 5(2):1122-42. PubMed ID: 26057626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.